The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Am J Physiol Gastrointest Liver Physiol. 2021 Sep 1;321(3):G298-G307. doi: 10.1152/ajpgi.00458.2020. Epub 2021 Jul 14.
Drug-induced liver injury is an emerging form of acute and chronic liver disease that may manifest as fatty liver. Amiodarone (AMD), a widely used antiarrhythmic drug, can cause hepatic injury and steatosis by a variety of mechanisms, not all completely understood. We hypothesized that repetitive AMD administration may induce hepatic lipotoxicity not only via effects on the liver but also via effects on adipose tissue. Indeed, repetitive AMD administration induced endoplasmic reticulum (ER) stress in both liver and adipose tissue. In adipose tissue, AMD reduced lipogenesis and increased lipolysis. Moreover, AMD treatment induced ER stress and ER stress-dependent lipolysis in 3T3L1 adipocytes in vitro. In the liver, AMD caused increased expression of genes encoding proteins involved in fatty acid (FA) uptake and transfer (, , and ), and resulted in increased hepatic accumulation of free FAs, but not of triacylglycerols. In line with this, there was increased expression of hepatic de novo FA synthesis genes. However, AMD significantly reduced the expression of the desaturase and elongase , detected at mRNA and protein levels. Accordingly, the FA profile of hepatic total lipids revealed increased accumulation of palmitate, an SCD1 and ELOVL6 substrate, and reduced levels of palmitoleate and -vaccenate, products of the enzymes. In addition, AMD-treated mice displayed increased hepatic apoptosis. The studies show that repetitive AMD induces ER stress and aggravates lipolysis in adipose tissue while inducing a lipotoxic hepatic lipid environment, suggesting that AMD-induced liver damage is due to compound insult to liver and adipose tissue. AMD chronic administration induces hepatic lipid accumulation by several mechanisms, including induction of hepatic ER stress, impairment of β-oxidation, and inhibition of triacylglycerol secretion. Our study shows that repetitive AMD treatment induces not only hepatic ER stress but also adipose tissue ER stress and lipolysis and hepatic accumulation of free fatty acids and enrichment of palmitate in the total lipids. Understanding the toxicity mechanisms of AMD would help devise ways to limit liver damage.
药物性肝损伤是一种新兴的急性和慢性肝病形式,可能表现为脂肪肝。胺碘酮(AMD)是一种广泛使用的抗心律失常药物,通过多种机制引起肝损伤和脂肪变性,并非所有机制都完全清楚。我们假设重复 AMD 给药不仅通过对肝脏的作用,而且通过对脂肪组织的作用引起肝脂肪毒性。事实上,重复 AMD 给药诱导肝和脂肪组织内质网(ER)应激。在脂肪组织中,AMD 减少脂肪生成并增加脂肪分解。此外,AMD 处理在体外诱导 3T3L1 脂肪细胞中的 ER 应激和 ER 应激依赖性脂肪分解。在肝脏中,AMD 引起编码参与脂肪酸(FA)摄取和转运的蛋白质的基因表达增加(、和),导致游离 FA 在肝脏中的积累增加,但三酰甘油没有增加。与此一致的是,肝从头合成 FA 的基因表达增加。然而,AMD 在 mRNA 和蛋白质水平上显著降低了去饱和酶和延伸酶的表达。因此,肝总脂质的 FA 谱显示棕榈酸(SCD1 和 ELOVL6 的底物)积累增加,棕榈油酸和 -桐酸(酶的产物)水平降低。此外,AMD 处理的小鼠显示肝凋亡增加。研究表明,重复 AMD 诱导脂肪组织内质网应激和脂肪分解加剧,同时诱导肝毒性脂质环境,表明 AMD 诱导的肝损伤是由于对肝脏和脂肪组织的复合损伤。AMD 慢性给药通过多种机制诱导肝脂质积累,包括诱导肝内质网应激、损害β-氧化和抑制三酰甘油分泌。我们的研究表明,重复 AMD 处理不仅诱导肝内质网应激,还诱导脂肪组织内质网应激和脂肪分解以及游离脂肪酸在肝中的积累和总脂质中棕榈酸的富集。了解 AMD 的毒性机制将有助于设计限制肝损伤的方法。